APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Bacterial Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Human Bacterial Vaccine Market Outlook and Growth Opportunities 2026

31 December 2025190 pages

Choose your research edition.

Industry ResearchHuman Bacterial Vaccine Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Bacterial Vaccine Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Human Bacterial Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Bacterial Vaccine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Bacterial Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Human Bacterial Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Human Bacterial Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Human Bacterial Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Bacterial Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Human Bacterial Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Human Bacterial Vaccine market include Emergent BioSolutions, Mitsubishi Tanabe Pharma, Bayer, GSK, Pfizer, Merck and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Human Bacterial Vaccine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Human Bacterial Vaccine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Human Bacterial Vaccine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Human Bacterial Vaccine market.

Human Bacterial Vaccine Segment by Company

Emergent BioSolutions

Mitsubishi Tanabe Pharma

Bayer

GSK

Pfizer

Merck

Sanofi

Human Bacterial Vaccine Segment by Type

Bacillus Anthracis

Haemophilus Influenzae

Salmonella Typhi

Clostridium Tetani

Streptococcus Pneumoniae

Pertussis

Others

Human Bacterial Vaccine Segment by Application

Elderly

Children

Adults

Human Bacterial Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Human Bacterial Vaccine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Human Bacterial Vaccine key companies, revenue, market share, and recent developments.

3. To split the Human Bacterial Vaccine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Human Bacterial Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Human Bacterial Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Human Bacterial Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Bacterial Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Bacterial Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Bacterial Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Bacterial Vaccine industry.

Chapter 3: Detailed analysis of Human Bacterial Vaccine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Human Bacterial Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Human Bacterial Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Human Bacterial Vaccine Industry Trends Table 2. Human Bacterial Vaccine Industry Drivers Table 3. Human Bacterial Vaccine Industry Opportunities and Challenges Table 4. Human Bacterial Vaccine Industry Restraints Table 5. Global Human Bacterial Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Human Bacterial Vaccine Revenue Share by Company (2021-2026) Table 7. Global Human Bacterial Vaccine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Human Bacterial Vaccine Key Company Manufacturing Base & Headquarters Table 9. Global Human Bacterial Vaccine Company, Product Type & Application Table 10. Global Human Bacterial Vaccine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Human Bacterial Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Bacillus Anthracis Table 15. Significant Companies of Haemophilus Influenzae Table 16. Significant Companies of Salmonella Typhi Table 17. Significant Companies of Clostridium Tetani Table 18. Significant Companies of Streptococcus Pneumoniae Table 19. Significant Companies of Pertussis Table 20. Significant Companies of Others Table 21. Global Human Bacterial Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 22. Global Human Bacterial Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 23. Global Human Bacterial Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 24. Global Human Bacterial Vaccine Sales Value Share by Type (2021-2026) Table 25. Global Human Bacterial Vaccine Sales Value Share by Type (2027-2032) Table 26. Significant Companies of Elderly Table 27. Significant Companies of Children Table 28. Significant Companies of Adults Table 29. Global Human Bacterial Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Human Bacterial Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Human Bacterial Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Human Bacterial Vaccine Sales Value Share by Application (2021-2026) Table 33. Global Human Bacterial Vaccine Sales Value Share by Application (2027-2032) Table 34. Global Human Bacterial Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Human Bacterial Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Human Bacterial Vaccine Sales Value Share by Region (2021-2026) Table 37. Global Human Bacterial Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Human Bacterial Vaccine Sales Value Share by Region (2027-2032) Table 39. Global Human Bacterial Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Human Bacterial Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Human Bacterial Vaccine Sales Value Market Share by Country (2021-2026) Table 42. Global Human Bacterial Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Human Bacterial Vaccine Sales Value Market Share by Country (2027-2032) Table 44. Emergent BioSolutions Company Information Table 45. Emergent BioSolutions Business Overview Table 46. Emergent BioSolutions Human Bacterial Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Emergent BioSolutions Human Bacterial Vaccine Product Portfolio Table 48. Emergent BioSolutions Recent Development Table 49. Mitsubishi Tanabe Pharma Company Information Table 50. Mitsubishi Tanabe Pharma Business Overview Table 51. Mitsubishi Tanabe Pharma Human Bacterial Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Mitsubishi Tanabe Pharma Human Bacterial Vaccine Product Portfolio Table 53. Mitsubishi Tanabe Pharma Recent Development Table 54. Bayer Company Information Table 55. Bayer Business Overview Table 56. Bayer Human Bacterial Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Bayer Human Bacterial Vaccine Product Portfolio Table 58. Bayer Recent Development Table 59. GSK Company Information Table 60. GSK Business Overview Table 61. GSK Human Bacterial Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. GSK Human Bacterial Vaccine Product Portfolio Table 63. GSK Recent Development Table 64. Pfizer Company Information Table 65. Pfizer Business Overview Table 66. Pfizer Human Bacterial Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Pfizer Human Bacterial Vaccine Product Portfolio Table 68. Pfizer Recent Development Table 69. Merck Company Information Table 70. Merck Business Overview Table 71. Merck Human Bacterial Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Merck Human Bacterial Vaccine Product Portfolio Table 73. Merck Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Human Bacterial Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Sanofi Human Bacterial Vaccine Product Portfolio Table 78. Sanofi Recent Development Table 79. Research Programs/Design for This Report Table 80. Authors List of This Report Table 81. Secondary Sources Table 82. Primary Sources List of Figures Figure 1. Human Bacterial Vaccine Product Image Figure 2. Global Human Bacterial Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Human Bacterial Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Human Bacterial Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Bacillus Anthracis Image Figure 8. Haemophilus Influenzae Image Figure 9. Salmonella Typhi Image Figure 10. Clostridium Tetani Image Figure 11. Streptococcus Pneumoniae Image Figure 12. Pertussis Image Figure 13. Others Image Figure 14. Global Human Bacterial Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Human Bacterial Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Human Bacterial Vaccine Sales Value Share by Type (2021-2032) Figure 17. Elderly Image Figure 18. Children Image Figure 19. Adults Image Figure 20. Global Human Bacterial Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Human Bacterial Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Human Bacterial Vaccine Sales Value Share by Application (2021-2032) Figure 23. Global Human Bacterial Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Human Bacterial Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Human Bacterial Vaccine Sales Value (2021-2032) & (US$ Million) Figure 26. North America Human Bacterial Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Human Bacterial Vaccine Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Human Bacterial Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Human Bacterial Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Human Bacterial Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Human Bacterial Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. South America Human Bacterial Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Human Bacterial Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Human Bacterial Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Human Bacterial Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Bacillus Anthracis
  • Haemophilus Influenzae
  • Salmonella Typhi
  • Clostridium Tetani
  • Streptococcus Pneumoniae
  • Pertussis
  • Others
Applications
  • Elderly
  • Children
  • Adults
Companies covered
  • Emergent BioSolutions
  • Mitsubishi Tanabe Pharma
  • Bayer
  • GSK
  • Pfizer
  • Merck
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Human Bacterial Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Human Bacterial Vaccine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Human Bacterial Vaccine Market Dynamics
  1. 2.1 Human Bacterial Vaccine Industry Trends
  2. 2.2 Human Bacterial Vaccine Industry Drivers
  3. 2.3 Human Bacterial Vaccine Industry Opportunities and Challenges
  4. 2.4 Human Bacterial Vaccine Industry Restraints
3 Human Bacterial Vaccine Market by Company
  1. 3.1 Global Human Bacterial Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Human Bacterial Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Human Bacterial Vaccine Company Ranking (2024-2026)
  4. 3.4 Global Human Bacterial Vaccine Company Manufacturing Base and Headquarters
  5. 3.5 Global Human Bacterial Vaccine Company Product Type and Application
  6. 3.6 Global Human Bacterial Vaccine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Human Bacterial Vaccine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Human Bacterial Vaccine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Human Bacterial Vaccine Market by Type
  1. 4.1 Human Bacterial Vaccine Type Introduction
  2. 4.1.1 Bacillus Anthracis
  3. 4.1.2 Haemophilus Influenzae
  4. 4.1.3 Salmonella Typhi
  5. 4.1.4 Clostridium Tetani
  6. 4.1.5 Streptococcus Pneumoniae
  7. 4.1.6 Pertussis
  8. 4.1.7 Others
  9. 4.2 Global Human Bacterial Vaccine Sales Value by Type
  10. 4.2.1 Global Human Bacterial Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Human Bacterial Vaccine Sales Value by Type (2021-2032)
  12. 4.2.3 Global Human Bacterial Vaccine Sales Value Share by Type (2021-2032)
5 Human Bacterial Vaccine Market by Application
  1. 5.1 Human Bacterial Vaccine Application Introduction
  2. 5.1.1 Elderly
  3. 5.1.2 Children
  4. 5.1.3 Adults
  5. 5.2 Global Human Bacterial Vaccine Sales Value by Application
  6. 5.2.1 Global Human Bacterial Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Human Bacterial Vaccine Sales Value by Application (2021-2032)
  8. 5.2.3 Global Human Bacterial Vaccine Sales Value Share by Application (2021-2032)
6 Human Bacterial Vaccine Regional Value Analysis
  1. 6.1 Global Human Bacterial Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Human Bacterial Vaccine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Human Bacterial Vaccine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Human Bacterial Vaccine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Human Bacterial Vaccine Sales Value (2021-2032)
  7. 6.3.2 North America Human Bacterial Vaccine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Human Bacterial Vaccine Sales Value (2021-2032)
  10. 6.4.2 Europe Human Bacterial Vaccine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Human Bacterial Vaccine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Human Bacterial Vaccine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Human Bacterial Vaccine Sales Value (2021-2032)
  16. 6.6.2 South America Human Bacterial Vaccine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Human Bacterial Vaccine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Human Bacterial Vaccine Sales Value Share by Country, 2025 VS 2032
7 Human Bacterial Vaccine Country-level Value Analysis
  1. 7.1 Global Human Bacterial Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Human Bacterial Vaccine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Human Bacterial Vaccine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Human Bacterial Vaccine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Human Bacterial Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Human Bacterial Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Human Bacterial Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Emergent BioSolutions
  2. 8.1.1 Emergent BioSolutions Company Information
  3. 8.1.2 Emergent BioSolutions Business Overview
  4. 8.1.3 Emergent BioSolutions Human Bacterial Vaccine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Emergent BioSolutions Human Bacterial Vaccine Product Portfolio
  6. 8.1.5 Emergent BioSolutions Recent Developments
  7. 8.2 Mitsubishi Tanabe Pharma
  8. 8.2.1 Mitsubishi Tanabe Pharma Company Information
  9. 8.2.2 Mitsubishi Tanabe Pharma Business Overview
  10. 8.2.3 Mitsubishi Tanabe Pharma Human Bacterial Vaccine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Mitsubishi Tanabe Pharma Human Bacterial Vaccine Product Portfolio
  12. 8.2.5 Mitsubishi Tanabe Pharma Recent Developments
  13. 8.3 Bayer
  14. 8.3.1 Bayer Company Information
  15. 8.3.2 Bayer Business Overview
  16. 8.3.3 Bayer Human Bacterial Vaccine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bayer Human Bacterial Vaccine Product Portfolio
  18. 8.3.5 Bayer Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Human Bacterial Vaccine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GSK Human Bacterial Vaccine Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Human Bacterial Vaccine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Human Bacterial Vaccine Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Human Bacterial Vaccine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck Human Bacterial Vaccine Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 Sanofi
  38. 8.7.1 Sanofi Company Information
  39. 8.7.2 Sanofi Business Overview
  40. 8.7.3 Sanofi Human Bacterial Vaccine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi Human Bacterial Vaccine Product Portfolio
  42. 8.7.5 Sanofi Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst